- $78.48m
- $32.52m
- $28.70m
- 26
- 30
- 43
- 24
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.33 | ||
| Price to Tang. Book | 1.54 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.73 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -87.79% | ||
| Return on Equity | -114.71% | ||
| Operating Margin | -230.99% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 4.05 | 0.89 | 0.11 | 7.38 | 28.7 | 5.1 | 3.85 | 23.82% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The Company's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet.
Directors
- Wouter Latour NEC (63)
- Andrei Floroiu PRE (48)
- Margaret Echerd SVP (60)
- Sean Tucker SVP
- Julie Cherrington IND (63)
- Todd Davis IND (60)
- Michael Finney IND (62)
- David Wheadon IND (63)
- Karen Wilson IND (58)
- Robert Yedid IND (63)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 14th, 1969
- Public Since
- March 17th, 1980
- No. of Shareholders
- 2,155
- No. of Employees
- 105
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 228,208,284
- Address
- 170 Harbor Way, Suite 300, SOUTH SAN FRANCISCO, 94080
- Web
- https://vaxart.com/
- Phone
- +1 6505503500
- Auditors
- WithumSmith Brown PC
Upcoming Events for VXRT
Vaxart Inc Annual Shareholders Meeting
Vaxart Inc Annual Shareholders Meeting
Q2 2025 Vaxart Inc Earnings Release
Similar to VXRT
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Vaxart share price?
As of Today at 23:56 UTC, shares in Vaxart are trading at $0.34. This share price information is delayed by 15 minutes.
How has the Vaxart share price performed this year?
Shares in Vaxart last closed at $0.34 and the price had moved by -60.29% over the past 365 days. In terms of relative price strength the Vaxart share price has underperformed the S&P500 Index by -62.66% over the past year.
What are the analyst and broker recommendations for Vaxart?
The overall consensus recommendation for Vaxart is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Vaxart dividend yield?
Vaxart does not currently pay a dividend.
Does Vaxart pay a dividend?
Vaxart does not currently pay a dividend.
When does Vaxart next pay dividends?
Vaxart does not currently pay a dividend.
How do I buy Vaxart shares?
To buy shares in Vaxart you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Vaxart?
As of the previous close price of $0.34, shares in Vaxart had a market capitalisation of $78.48m.
Where are Vaxart shares listed?
Here are the trading details for Vaxart:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: VXRT
What kind of share is Vaxart?
Based on an overall assessment of its quality, value and momentum Vaxart is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Vaxart share price forecast for 2025?
The analyst consensus target price for shares in Vaxart is $4.67. That is 1257.95% above the last closing price of $0.34.
Analysts covering Vaxart currently have a consensus Earnings Per Share (EPS) forecast of -$0.31 for the next financial year.
Find out moreWhat is the trend in the Vaxart share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vaxart. Over the past six months, its share price has underperformed the S&P500 Index by -53.51%.
As of the last closing price of $0.34, shares in Vaxart were trading -49.29% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Vaxart PE Ratio?
The Vaxart PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.34.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Vaxart?
Vaxart's management team is headed by:
- Wouter Latour - NEC
- Andrei Floroiu - PRE
- Margaret Echerd - SVP
- Sean Tucker - SVP
- Julie Cherrington - IND
- Todd Davis - IND
- Michael Finney - IND
- David Wheadon - IND
- Karen Wilson - IND
- Robert Yedid - IND